Reply
Kristopher Croome, Roberto Hernandez‐Alejandro – 31 January 2014
Liver transplantation for alcoholic cirrhosis in Japan
Michael R. Lucey – 30 January 2014
Is the aerobic capacity at the time of cardiopulmonary exercise testing useful in predicting survival following liver transplantation?
Rebecca Young, Nick Murphy, Ahmed M. Elsharkawy – 30 January 2014
Effects of air embolism size and location on porcine hepatic microcirculation in machine perfusion
Maria‐Louisa Izamis, Andreas Efstathiades, Christina Keravnou, Soteria Georgiadou, Paulo N. Martins, Michalakis A. Averkiou – 30 January 2014 – The handling of donor organs frequently introduces air into the microvasculature, but little is known about the extent of the damage caused as a function of the embolism size and distribution. Here we introduced embolisms of different sizes into the portal vein, the hepatic artery, or both during the flushing stage of porcine liver procurement.
Statin therapy is associated with the development of new‐onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels
Yongin Cho, Min Jung Lee, Eun Yeong Choe, Chang Hee Jung, Dong Jin Joo, Myoung Soo Kim, Bong Soo Cha, Joong‐Yeol Park, Eun Seok Kang – 30 January 2014 – New‐onset diabetes after transplantation (NODAT) and dyslipidemia are important metabolic complications after liver transplantation (LT) that can adversely affect both allograft and patient survival. Statins are used as first‐line therapies for dyslipidemia because of their effectiveness and safety profile. However, it has recently been reported that statin therapy is associated with new‐onset diabetes in the nontransplant population.
Long‐term outcomes after liver transplantation for deoxyguanosine kinase deficiency: A single‐center experience and a review of the literature
Enke Grabhorn, Konstantinos Tsiakas, Uta Herden, Lutz Fischer, Peter Freisinger, Thorsten Marquardt, Rainer Ganschow, Andrea Briem‐Richter, René Santer – 30 January 2014 – Deoxyguanosine kinase (DGUOK) deficiency is a well‐known cause of hepatocerebral mitochondrial DNA depletion syndromes, which include a broad spectrum of clinical presentations. Affected patients often develop life‐threatening liver failure, but the benefits of liver transplantation (LT) are controversial because of the frequently severe neurological involvement due to the underlying mitochondrial disease.
National assessment of early biliary complications following liver transplantation: Incidence and outcomes
David A. Axelrod, Krista L. Lentine, Huiling Xiao, Nino Dzebisashvilli, Mark Schnitzler, Janet E. Tuttle‐Newhall, Dorry L. Segev – 30 January 2014 – Despite improved overall liver transplant outcomes, biliary complications remain a significant cause of morbidity. A national data set linking transplant registry and Medicare claims data for 17,012 liver transplant recipients was used to identify all recipients with a posttransplant biliary diagnosis code within the first 6 months after transplantation.
Reply
Katharine Secunda, Josh Levitsky – 30 January 2014
Liver transplantation for hepatocellular carcinoma with allografts from donors after circulatory death: Is the tumor recurrence genuinely increased?
Hynek Mergental, Firas Zahr Eldeen, Paolo Muiesan, Darius Mirza – 30 January 2014
No increase in blood transfusions during liver transplantation since the withdrawal of aprotinin
Nick Schofield, Anita Sugavanam, Karen Thompson, Susan V. Mallett – 30 January 2014 – The aims of this study were to determine whether the withdrawal of aprotinin (APRO) led to an increased bleeding risk in patients undergoing orthotopic liver transplantation (OLT). A retrospective analysis compared consecutive patients undergoing OLT and treated with aprotinin (APRO group; n = 100) with a group in which aprotinin was not used (no‐APRO group; n = 100). Propensity score matching was then performed for each group to identify 2 matched cohorts.